Table 4.

Cox proportional hazards analysis of overall survival (placebo plus chemotherapy arm)

Covariate	Hazard ratio (95% CI)	p value
Japan vs. USA/western Europe	0.81 (0.57–1.14)	0.2270
Korea and other Asia vs. USA/western Europe	0.82 (0.57–1.18)	0.2936
Eastern Europe/South America vs. USA/western Europe	1.52 (1.10–2.14)	0.0170
Sex (female vs. male)	1.01 (0.80–1.28)	0.9275
Age (< 65 vs. ≥ 65 years)	0.90 (0.70–1.16)	0.4050
ECOG performance status (0 vs. ≥ 1)	0.73 (0.57–0.93)	0.0116
Primary site (gastroesophageal junction vs. stomach)	1.11 (0.77–1.60)	0.5754
Disease status (locally advanced vs. metastatic)	2.81 (1.33–5.92)	0.0067
Liver metastases (no vs. yes)	0.71 (0.53–0.94)	0.0161
Histological type (diffuse vs. mixed)	0.98 (0.62–1.57)	0.9434
Histological type (intestinal vs. mixed)	0.75 (0.47–1.22)	0.2473
Prior gastrectomy (no vs. yes)	1.61 (1.23–2.11)	0.0006
Prior (neo)adjuvant therapy (no vs. yes)	0.74 (0.49–1.12)	0.1510
Tumor size (< 40 mm vs. not measurable)	1.17 (0.86–1.58)	0.3251
Tumor size (≥ 40 mm vs. not measurable)	1.04 (0.74–1.46)	0.8259
Bone metastases (no vs. yes)	0.45 (0.25–0.78)	0.0050
Peritoneal metastases (no vs. yes)	0.55 (0.42–0.73)	< 0.0001
Number of metastatic sites (> 1 vs. ≤ 1)	0.96 (0.73–1.26)	0.7584

ECOG Eastern Cooperative Oncology Group